Search - tctmd.com

Displaying 21 - 40 of 193

Sort: Relevancy | Date

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Presentation TCT 2024

TCT 286: Impact of Dual Antiplatelet Therapy on Secondary Revascularization due to Native Vessel Disease Progression v/s Graft Failure After Coronary Artery Bypass Graft

Presenter: IFTIKHAR CH

October 27, 2024

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

News Conference News TCT 2023

PARTHENOPE Adds to Polymer-Free Stent Data, But Raises ST Questions

October 31, 2023

TCT 781: Clinical outcomes of patients treated using 1-month dual antiplatelet therapy after biodegradable-polymer DES implantation

Presentation TCT 2023

TCT 781: Clinical outcomes of patients treated using 1-month dual antiplatelet therapy after biodegradable-polymer DES implantation

Presenter: Masaru Ishida

October 26, 2023

TCT 706: 3-6 Month vs 12 Month Dual Antiplatelet Therapy After Drug Eluting Stent Placement: An Updated Meta-Analysis

Presentation TCT 2023

TCT 706: 3-6 Month vs 12 Month Dual Antiplatelet Therapy After Drug Eluting Stent Placement: An Updated Meta-Analysis

Presenter: Aakash Garg

October 25, 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

News Conference News TCT 2023

‘Light at the End of the Tunnel’ for In-Stent Restenosis: AGENT IDE Wins Big

October 25, 2023

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

Presentation TCT 2023

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

Presenter: Seong Huan Choi

October 25, 2023

TCT 603: Single versus Dual Antiplatelet Therapy for Conservatively Managed Spontaneous Coronary Artery Dissection (SCAD) Patients

Presentation TCT 2023

TCT 603: Single versus Dual Antiplatelet Therapy for Conservatively Managed Spontaneous Coronary Artery Dissection (SCAD) Patients

Presenter: Sophie Offen

October 25, 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presentation TCT 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presenter: Ji-Yeon Kim

October 25, 2023

TCT 30: Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

Presentation TCT 2023

TCT 30: Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

Presenter: Byeong-Keuk Kim

October 25, 2023

Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial

Presentation TCT 2023

Less Than 1-Month Dual Antiplatelet Therapy Followed by Ticagrelor Monotherapy After Coronary Drug-Eluting Stent Implantation for Acute Coronary Syndrome: A Randomized Trial

Presenter: Myeong-Ki Hong

October 25, 2023

TCT 7: Strategy of Dual Antiplatelet Therapy for Patients With ST elevation myocardial infarction or Non-ST elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis

Presentation TCT 2023

TCT 7: Strategy of Dual Antiplatelet Therapy for Patients With ST elevation myocardial infarction or Non-ST elevation Acute Coronary Syndrome: A Systematic Review and Network Meta-Analysis

Presenter: Toshiki Kuno

October 24, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

Dual Antiplatelet Therapy After PCI: Considerations for Duration and Choice Of Drug(s)

Presentation TCT 2023

Dual Antiplatelet Therapy After PCI: Considerations for Duration and Choice Of Drug(s)

Presenter: Jacqueline Tamis-Holland

October 24, 2023

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

News Conference News TCT 2022

RIVARAD: Rivaroxaban a Possible Solution to Radial Artery Occlusion

September 21, 2022

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presentation TCT 2022

TCT 151: Dual Antiplatelet Therapy after Percutaneous Coronary Intervention for Left Main Coronary Artery Disease

Presenter: Sungsoo Cho

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

News Conference News TCT 2022

Amulet, Watchman 2.5 LAAO Devices Provide Comparable 3-Year Outcomes

September 18, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.